Largecap pharma major rises over 4% to clinch all-time high: Here's all you need to know

Divi's Laboratories shares in Monday's trade rallied to a new all-time high of Rs 6,764 per share, rising over 4 per cent. At around 1 pm, shares of the largecap company traded with gains of 3.77 per cent or Rs 244.05 at Rs 6,724.75 per share on the BSE.

Divi's Laboratories inks a long-term manufacturing and supply agreeement

Divis Laboratories has inked a long term manufacturing and supply agreement with a global pharma company. Under this agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties.

The company expects meaningful revenue contribution from this long-term agreement. For the same, the company's capex is estimated to amount to Rs 650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement.

Divis Laboratories believes the partnership will not only ensure a reliable supply chain but also allow the company to strengthen its foothold in the custom synthesis space.

The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.

Divi's Q4FY25 results

The company's consolidated net profit jumped 23.04 per cent to Rs 662 crore while revenue from operations grew by 12.24 per cent to Rs 2,585 crore in Q4 March 2025 in comparison to the same quarter last year.

Divi's Laboratories' share price performance

In the last one year, shares of the pharma major have gained 24 per cent.